Drug profile · INN
panitumumab
VECTIBIX
panitumumab (VECTIBIX) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Amgen. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — panitumumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- IV (INFUSION)
- Patents
- 0
- Programs
- 22
- Data quality
- 0.84
Quick answer
panitumumab (VECTIBIX) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Amgen. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is panitumumab?
panitumumab (VECTIBIX) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Amgen. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for panitumumab?
VECTIBIX is a marketed brand name for panitumumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of panitumumab?
panitumumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.